A brief history in nephrology pharmacotherapy.
Advances in drug therapy for patients with kidney disease have contributed to increased exercise capacity, reduced cardiovascular disease, decreased renal bone disease, improved quality of life, and most importantly, reduced morbidity and mortality. New insights into the pathophysiology of chronic kidney disease (CKD) have helped lead to the development of many novel drugs and treatments. The purpose of this article is to highlight some of the developments in nephrology pharmacotherapy that occurred during the first 40 years of the American Nephrology Nurses' Association.
Quan
David J
DJ
Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, CA, USA.
D018798:Anemia, Iron-Deficiency / Q000266:history; D002614:Chelating Agents / Q000266:history; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000266:history; D004358:Drug Therapy / Q000266:history*; D006397:Hematinics / Q000266:history; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007166:Immunosuppressive Agents / Q000266:history; D007676:Kidney Failure, Chronic / Q000266:history*; D016030:Kidney Transplantation / Q000266:history; D009398:Nephrology / Q000266:history*; D013041:Specialties, Nursing / Q000266:history*
D002614:Chelating Agents; D006397:Hematinics; D007166:Immunosuppressive Agents